Antibody seroprevalence against SARS-CoV-2 within the Canton of Sarajevo, Bosnia and Herzegovina-One year later

PLoS One. 2022 Mar 31;17(3):e0265431. doi: 10.1371/journal.pone.0265431. eCollection 2022.

Abstract

Background: Serostudies are important resources when following pandemics and predicting their further spread, as well as determining the length of protection against reinfection and vaccine development. The aim of this study was to update data on the prevalence of seropositive individuals in Canton Sarajevo, Bosnia and Herzegovina (B&H) from September 2020 to May 2021.

Methods: Anti-SARS-CoV-2 antibodies were quantified using an electrochemiluminescence immunoassay.

Results: Compared to the period April-July 2020, when anti-SARS-CoV-2 antibodies were detected in 3.77% of samples, one year later (May 2021) the estimated percentage within the same population of the urban Canton Sarajevo was 29.9% (5,406/18,066). Of all anti-SARS-CoV-2 Ig-positive individuals, 53.27% were men, and 69.00% were of 50 years of age or younger. Also, the current update found the individuals 50 years of age or younger to be more frequently anti-SARS-CoV-2 Ig positive compared to older individuals. On the other hand, higher median anti-SARS-CoV-2 Ig levels were found in individuals > 50 years old than in younger individuals, as well as in men compared to women. Seropositivity gradually increased from September 2020 to May 2021, with the lowest frequency of positive cases (3.5%) observed in September 2020, and the highest frequency (77.7%) in January 2021.

Conclusion: Our results provided important seroprevalence data that could help in planning restrictive local public health measures to protect the population of Sarajevo Canton, especially considering that at the time of the study the vaccines were virtually inaccessible to the general population not belonging to any of the high-priority groups for vaccination.

MeSH terms

  • Antibodies, Viral
  • Bosnia and Herzegovina / epidemiology
  • COVID-19* / epidemiology
  • Female
  • Humans
  • Male
  • Middle Aged
  • SARS-CoV-2*
  • Seroepidemiologic Studies

Substances

  • Antibodies, Viral

Grants and funding

The author(s) received no specific funding for this work.